Elevated Interleukin-6 Levels in Covid-19-Infected Patients Are Associated With Major Adverse Cardiac Events and/or Mortality

Nguyen, Nathalie; Ukoha, Chijioke; Ikram, Farukh; Patel, Chirag; Nguyen, Ha Q.; Hoang, Lawrence; Acharya, Priyanka; Dhillon, Anmol; Sidhu, Manavjot S.

doi:10.1016/s0735-1097(21)04498-3

Search citation statements

Order By: Relevance

Paper Sections

Select...

Interleukin 6 Levels In Severe Covid-19 Infection Versus Non...1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also linked with elevated levels of GGT, ALT and AST during hospitalization of COVID-19 patient [25] . A study conducted on 225 COVID-19 patients in Southwest quaternary United states hospital reported that a positive correlation between IL-6 levels and adverse cardiac events or deaths [26] . Recent data from COVID-19 patients with diabetes have found elevated levels of systemic IL-6 compared to patients without diabetes [27] .…”

Section: Interleukin 6 Levels In Severe Covid-19 Infection Versus Non...mentioning

confidence: 99%

Interleukin 6: A biomarker for COVID-19 progression

Sebbar

Choukri

2023

Materials Today: Proceedings

View full text Add to dashboard Cite

Section: Interleukin 6 Levels In Severe Covid-19 Infection Versus Non...mentioning

confidence: 99%

Interleukin 6: A biomarker for COVID-19 progression

Sebbar

Choukri

2023

Materials Today: Proceedings

View full text Add to dashboard Cite

Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19

et al. 2022

View full text Add to dashboard Cite

Interleukin-6 (IL-6) has been linked to several life-threatening disease processes. Developing a point-of-care testing platform for the immediate and accurate detection of IL-6 concentrations could present a valuable tool for improving clinical management in patients with IL-6-mediated diseases. Drawing on an available biobank of samples from 35 patients hospitalized with COVID-19, a novel quantum-magnetic sensing platform is used to determine plasma IL-6 concentrations. A strong correlation was observed between IL-6 levels measured by QDTI10x and the Luminex assay (r = 0.70, p-value < 0.001) and between QDTI80x and Luminex (r = 0.82, p-value < 0.001). To validate the non-inferiority of QDTI to Luminex in terms of the accuracy of IL-6 measurement, two clinical parameters—the need for intensive care unit admission and the need for mechanical intubation—were chosen. IL-6 concentrations measured by the two assays were compared with respect to these clinical outcomes. Results demonstrated a comparative predictive performance between the two assays with a significant correlation coefficient. Conclusion: In short, the QDTI assay holds promise for implementation as a potential tool for rapid clinical decision in patients with IL-6-mediated diseases. It could also reduce healthcare costs and enable the development of future various biomolecule point-of-care tests for different clinical scenarios.

show abstract

Elevated Interleukin-6 Levels in Covid-19-Infected Patients Are Associated With Major Adverse Cardiac Events and/or Mortality

Cited by 2 publications

References 0 publications

Interleukin 6: A biomarker for COVID-19 progression

Interleukin 6: A biomarker for COVID-19 progression

Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19

Contact Info

Product

Resources

About